Clinical Practice & Guidelines Flashcards

A 68-year-old patient with CKD stage 3b (eGFR 38 mL/min/1.73m²) and type 2 diabetes presents with an HbA1c of 9.2%. According to DHA-aligned evidence-based guidelines, which antidiabetic agent requires the most critical dose adjustment or avoidance in this patient?

Answer: Metformin

Metformin is contraindicated or requires significant caution at eGFR <30, but DHA/international guidelines recommend dose reduction (not discontinuation) at eGFR 30–45. However, it requires the most critical reassessment because lactic acidosis risk rises at this eGFR threshold. SGLT2 inhibitors like empagliflozin lose glycemic efficacy below eGFR 45 but are now allowed for cardiorenal benefit. Sitagliptin requires dose reduction (50 mg/day at eGFR 30–49). Glipizide is relatively safer in CKD due to inactive metabolites. Metformin's risk-benefit calculation at this exact eGFR is the most clinically critical decision point.

During a ward round, a physician writes an order for 'morphine 10 mg IV PRN for pain.' According to DHA medication safety guidelines and Joint Commission International standards adopted in UAE, what is the primary deficiency in this order?

Answer: The order lacks a minimum dosing interval and maximum daily dose ceiling

A PRN opioid order without a specified minimum interval (e.g., 'q4h PRN') and a 24-hour dose ceiling is a recognized high-alert medication safety gap per JCI and DHA medication management standards. Without these parameters, nursing staff cannot determine when re-dosing is appropriate, increasing overdose risk. IV morphine PRN is not prohibited in inpatient settings, and 10 mg IV is not categorically excessive. The critical deficiency is the absence of frequency and ceiling dose parameters.

A 45-year-old woman presents to an outpatient DHA clinic requesting a repeat prescription for a benzodiazepine she has used daily for 3 years. She has no psychiatric follow-up. Under UAE Federal Law No. 14 of 1995 (Narcotics and Psychotropic Substances) and DHA prescribing regulations, what is the most appropriate immediate action?

Answer: Renew the prescription for 30 days and refer to psychiatry

DHA regulations permit short-term benzodiazepine prescribing in outpatient settings but require specialist oversight for chronic use. The most appropriate action is a bridging 30-day prescription to prevent acute withdrawal (which can be life-threatening) while simultaneously initiating a formal psychiatric referral for long-term management and supervised tapering. Outright refusal risks precipitating dangerous withdrawal. A 90-day renewal without specialist oversight violates DHA chronic psychotropic prescribing guidelines. Independent tapering without psychiatric support is below the standard of care for a 3-year daily user.

A surgeon in a DHA hospital plans an elective laparoscopic cholecystectomy on a patient taking rivaroxaban 20 mg/day for non-valvular atrial fibrillation. The patient's CrCl is 52 mL/min. Per current perioperative anticoagulation guidelines endorsed by DHA, what is the correct bridging and timing strategy?

Answer: Stop rivaroxaban 24 hours pre-operatively; no bridging required for low-to-moderate bleed risk surgery

For direct oral anticoagulants (DOACs) like rivaroxaban, current evidence-based perioperative guidelines (ACC/AHA, ESC — all adopted into DHA practice frameworks) recommend stopping rivaroxaban 24 hours before low-to-moderate bleeding risk procedures. Bridging with LMWH or UFH is NOT recommended for DOAC-treated AF patients because DOACs have predictable pharmacokinetics, and bridging increases bleeding without reducing thromboembolism. The 48-hour stoppage with LMWH bridge applies to warfarin, not DOACs. Five-day stoppage is for warfarin. Continuing through surgery is incorrect given the measurable residual drug effect within 24 hours.

In a DHA-accredited emergency department, a 29-year-old pregnant woman at 34 weeks gestation presents with blood pressure 158/104 mmHg on two readings 6 minutes apart, 2+ proteinuria, and a severe headache. She has no prior hypertension history. The fetal CTG shows a Category I tracing. What is the most appropriate first-line antihypertensive agent per DHA/WHO guidelines for acute severe hypertension in pregnancy?

Answer: IV labetalol 20 mg bolus

IV labetalol is the preferred first-line agent for acute severe hypertension in pregnancy in most DHA/WHO-aligned and ACOG guidelines, given its rapid onset, safety profile, and ability to avoid reflex tachycardia. IV hydralazine was historically first-line but is now second-line due to unpredictable response and higher rates of maternal hypotension and fetal distress. Oral nifedipine IR (not ER) is an acceptable alternative when IV access is unavailable, but ER formulation has delayed onset inappropriate for acute severe hypertension. Oral methyldopa is for chronic management only, with onset too slow for an acute hypertensive emergency.

A DHA hospital quality committee is reviewing a case where a patient received 10 times the prescribed dose of insulin due to a verbal order misinterpretation. Under the DHA Patient Safety framework and WHO Global Patient Safety Challenge, this event must be classified as:

Answer: A sentinel event requiring root cause analysis and mandatory DHA notification within 24 hours

A 10-fold insulin overdose resulting from a verbal order error meets the threshold of a sentinel event under DHA Patient Safety Policy and JCI standards. Sentinel events require: (1) immediate disclosure to the patient/family, (2) a comprehensive root cause analysis (RCA) within 45 days, and (3) mandatory notification to DHA within 24 hours of discovery regardless of patient outcome. The fact that the patient may have recovered does not downgrade the event classification. Pharmacovigilance reporting to the UAE Centre applies to adverse drug reactions from correctly administered drugs, not dosing errors. Near-miss classification would only apply if the error was caught before administration.